Hemochromatosis mutations in the general population: iron overload progression rate

Blood - Tập 103 - Trang 2914-2919 - 2004
Rolf Værn Andersen, Anne Tybjærg-Hansen, Merete Appleyard, Henrik Birgens, Børge Grønne Nordestgaard

Tóm tắt

Abstract

The progression rate of iron overload in hereditary hemochromatosis in individuals in the general population is unknown. We therefore examined in the general population iron overload progression rate in C282Y homozygotes. Using a cohort study of the Danish general population, The Copenhagen City Heart Study, we genotyped 9174 individuals. The 23 C282Y homozygotes identified were matched to 2 subjects each of 5 other HFE genotypes with respect to sex, age, and alcohol consumption. As a function of biologic age, transferrin saturation increased from 50% to 70% from 25 to 85 years of age and from 70% to 80% from 35 to 80 years of age in female and male C282Y homozygotes, respectively. Equivalently, ferritin levels increased from 100 to 500 μg/L and decreased from 800 to 400 μg/L in female and male C282Y homozygotes. As a function of 25 years follow-up irrespective of age, transferrin saturation and ferritin levels increased slightly in male and female C282Y homozygotes. None of the C282Y homozygotes developed clinically overt hemochromatosis. In conclusion, individuals in the general population with C282Y homozygosity at most demonstrate modest increases in transferrin saturation and ferritin levels, and clinically overt hemochromatosis is rare. Therefore, C282Y homozygotes identified during population screening, and not because of clinically overt hemochromatosis, at most need to be screened for manifestations of hemochromatosis every 10 to 20 years. (Blood. 2004;103: 2914-2919)


Tài liệu tham khảo

Beutler E, Bothwell TH, Charlton RW, Motulsky AG. Hereditary hemochromatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001: 3127-3161. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet.1996;13: 399-408. Barton JC, Bertoli LF. Hemochromatosis: the genetic disorder of the twenty-first century. Nat Med.1996;2: 394-395. Smith BN, Kantrowitz W, Grace ND, et al. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor? Hepatology.1997;25: 1439-1446. Edwards CQ, Griffen LM, Ajioka RS, Kushner JP. Screening for hemochromatosis: phenotype versus genotype. Semin Hematol.1998;35: 72-76. Adams PC. Population screening for hemochromatosis. Hepatology.1999;29: 1324-1327. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet.2002;359: 211-218. Åsberg A, Hveem K, Krüger Ø, Bjerve KS. Persons with screening-detected haemochromatosis: as healthy as the general population? Scand J Gastroenterol.2002;37: 719-724. Jackson HA, Carter K, Darke C, et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol.2001;114; 474-484. Åsberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol.2001;36: 1108-1115. Beaumont C, Simon M, Fauchet R, et al. Serum ferritin as a possible marker of the hemochromatosis allele. N Engl J Med.1979;301: 169-174. Meyer T, Baynes R, Bothwell T, et al. Phenotypic expression of the HLA linked iron-loading gene in males over the age of 40 years: a population study using serial serum ferritin estimations. J Intern Med.1990;227: 397-406. Milman N, Clausen JO, Jordal R. Iron status in young Danish men and women: a population survey comprising 548 individuals. Ann Hematol.1995;70: 215-221. Bassett ML, Halliday JW, Ferris RA, Powell LW. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology.1984;87: 628-633. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes in patients attending a health appraisal clinic. Ann Intern Med.2000;133: 329-337. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med.1999;341: 718-724. Crawford DH, Jazwinska EC, Cullen LM, Powell LW. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology.1998;114: 1003-1008. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen.1996;3: 178-184. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med.2000;343: 1529-1535. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet.2001;358: 1405-1409. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study: tables with data from the third examination 1991-1994. Eur Heart J Suppl.2001;3: 1-83. SPSS Base 8.0 for Windows User's Guide and SPSS Interactive Graphics 8.0. Chicago, IL: SPSS Inc; 1998. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology.1998;115: 929-936. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol.1998;35: 55-71. Willis G, Wimperis JZ, Lonsdale R, et al. Incidence of liver disease in people with HFE mutations. Gut.2000;46: 401-404. Merryweather-Clarke AT, Simonsen H, Shearman JD, et al. A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat.1999;13: 154-159.
Thông tin
Thông tin xuất bản

Blood

Tập 103

2914-2919

Thông tin tác giả